Articles: function.
-
Critical Care Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Velocity vector imaging (VVI) has been used to evaluate right ventricular (RV) strain pattern in patients with pulmonary artery hypertension. However, there is limited information on the utility of VVI and modern echocardiographic measurements (e.g. RV/LV end diastolic ratio, Tricuspid annular plane systolic excursion (TASPE), etc.) in predicting ICU and long-term mortality in acute pulmonary embolism (PE). ⋯ The following authors have nothing to disclose: Danai Khemasuwan, Teerapat Yingchoncharoen, Pichapong Tunsupon, Kenya Kusunose, Allan Klein, Ajit Moghekar, Adriano TonelliNo Product/Research Disclosure Information.
-
Lung Cancer Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Oxidative stress is increased in lung cancer (LC) and generated volatile organic compounds (VOC). We can detect VOC in exhaled breath using the analytical technique Thermal desorber-gase cromatography and mass spectrometry (TD-GC/MS). The determination of VOC, may be useful as a noninvasive screening in LC. ⋯ The following authors have nothing to disclose: Javier Jareño, Maria Angeles Munoz, Carolin Wagner, Concepcion Civera, Luis CallolNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Evaluate the impact of lung disease(COPD) chronic obstructive in the quality of life of these patients in the province of Albacete. ⋯ The following authors have nothing to disclose: José Luis Castro Navarro, Miguel Angel Palomino Medina, Pedro J. Tárraga López, Juan Solera Albero, Angel Celada Rodríguez, Enrique Arjona LabordaNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We want to share our experience with extracorporeal membrane oxigenation system (ECMO) in the management of a primary graft dysfunction after lung transplantation. ⋯ The following authors have nothing to disclose: José González García, Sebastian Peñafiel, Eugenia Libreros Niño, Diana Baquero Velandia, Victor Calvo Medina, Carlos Jordá Aragón, Gabriel Sales Badia, Juan Escrivá, Ángel García Zarza, Juan Pastor GuillemNo Product/Research Disclosure Information.